Publicacions en què col·labora amb Ignacio Melero (25)

2020

  1. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer

    European Journal of Cancer, Vol. 135, pp. 173-182

2019

  1. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

  2. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity

    Haematologica

  3. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

  4. Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15

    OncoImmunology, Vol. 7, Núm. 2

2017

  1. Antibody-dependent cell cytotoxicity: Immunotherapy strategies enhancing effector NK cells

    Immunology and Cell Biology, Vol. 95, Núm. 4, pp. 347-355

  2. Targeting NK-cell checkpoints for cancer immunotherapy

    Current Opinion in Immunology, Vol. 45, pp. 73-81

2016

  1. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2015

  1. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12

    Cancer Research, Vol. 75, Núm. 3, pp. 497-507

2008

  1. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis

    European Journal of Immunology, Vol. 38, Núm. 2, pp. 576-586

2007

  1. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions

    Journal of Investigative Dermatology, Vol. 127, Núm. 7, pp. 1673-1680

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

2005

  1. Aplicaciones actuales y futuras de la inmunoterapia adoptiva con linfocitos activados

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 9, Núm. 33, pp. 2202-2205

  2. Critical appraisal of the current status of dendritic cell based therapy

    Inmunologia, Vol. 24, Núm. 1, pp. 23-32

  3. Desarrollo de protocolos de inmunoterapia tumoral con células dendríticas

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 9, Núm. 33, pp. 2199-2201

  4. Desarrollo de un producto de terapia génica: desde el laboratorio a la clínica

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 9, Núm. 33, pp. 2206-2208

2004

  1. Inmunoterapia activa en el tratamiento de neoplasias hematológicas

    Anales del sistema sanitario de Navarra, Vol. 27, Núm. 1, pp. 45-62

  2. Past, present and future of anti-idiotype vaccination

    Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23